Show simple item record

dc.contributor.authorDudics, S.
dc.contributor.authorVenkatesha, S.H.
dc.contributor.authorMoudgil, K.D.
dc.date.accessioned2019-04-29T19:00:55Z
dc.date.available2019-04-29T19:00:55Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85052081100&doi=10.3390%2fijms19082293&partnerID=40&md5=8ed9b928a86b6f819ec61eaae4e69cc7
dc.identifier.urihttp://hdl.handle.net/10713/8881
dc.description.abstractRheumatoid arthritis (RA) is a chronic autoimmune disease of the joints affecting about 0.3-1% of the population in different countries. About 50-60 percent of RA patients respond to presently used drugs. Moreover, the current biomarkers for RA have inherent limitations. Consequently, there is a need for additional, new biomarkers for monitoring disease activity and responsiveness to therapy of RA patients. We examined the micro-RNA (miRNA) profile of immune (lymphoid) cells of arthritic Lewis rats and arthritic rats treated with celastrol, a natural triterpenoid. Experimental and bioinformatics analyses revealed 8 miRNAs (miR-22, miR-27a, miR-96, miR-142, miR-223, miR-296, miR-298, and miR-451) and their target genes in functional pathways important for RA pathogenesis. Interestingly, 6 of them (miR-22, miR-27a, miR-96, miR-142, miR-223, and miR-296) were further modulated by celastrol treatment. Interestingly, serum levels of miR-142, miR-155, and miR-223 were higher in arthritic versus control rats, whereas miR-212 showed increased expression in celastrol-treated rats compared with arthritic rats or control rats. This is the first study on comprehensive miRNA expression profiling in the adjuvant-induced arthritis (AA) model and it also has revealed new miRNA targets for celastrol in arthritis. We suggest that subsets of the above miRNAs may serve as novel biomarkers of disease activity and therapeutic response in arthritis. Copyright 2018 by the authors. Licensee MDPI, Basel, Switzerland.en_US
dc.description.sponsorshipFunding: This research was supported by R01 AT004321 (to K.D.M.) and F31 AT009421 (S.D.) grants from the National Institutes of Health (NIH), Bethesda, MD, and in part by Merit Review Award # 5 I01 BX002424 (to K.D.M.) from the United States (U.S.) Department of Veterans Affairs (Biomedical Laboratory Research and Development Service).en_US
dc.description.urihttps://dx.doi.org/10.3390/ijms19082293en_US
dc.language.isoen_USen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.subjectAdjuvant arthritisen_US
dc.subjectArthritisen_US
dc.subjectBiomarkersen_US
dc.subjectCelastrolen_US
dc.subjectInflammationen_US
dc.subjectmicroRNAen_US
dc.subjectmiRNAen_US
dc.subjectRaten_US
dc.subjectRheumatoid arthritisen_US
dc.subjectTraditional chinese medicineen_US
dc.subjectTripterineen_US
dc.subjectTriterpenoiden_US
dc.titleThe micro-RNA expression profiles of autoimmune arthritis reveal novel biomarkers of the disease and therapeutic responseen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/ijms19082293
dc.identifier.pmid30081592


This item appears in the following Collection(s)

Show simple item record